We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+5.19%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.34B
AUM Growth
+$16.4M
Cap. Flow
-$1.65M
Cap. Flow %
-0.12%
Top 10 Hldgs %
51.3%
Holding
73
New
15
Increased
18
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$54.1M
2
BSX icon
Boston Scientific
BSX
+$40.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$40.2M
4
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$34.8M
5
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$22.4M

Top Sells

Rank Stock Value
1
RAD
Rite Aid Corporation
RAD
+$49M
2
CMRX
Chimerix, Inc.
CMRX
+$40.8M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.8M
4
ZSPH
ZS PHARMA INC COMS TK (DE)
ZSPH
+$33.8M
5
INCY icon
Incyte
INCY
+$28.5M

Sector Composition

Rank Sector Weight
1 Healthcare 87.97%
2 Miscellaneous 9.9%
3 Communication Services 1.56%
4 Industrials 0.57%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOLD
1
DELISTED
Amicus Therapeutics
FOLD
$99.7M 7.46%
10,280,620
+1,947,690
+23% +$17.6M
MDVN
2
DELISTED
MEDIVATION, INC.
MDVN
$77.3M 5.79%
1,599,393
-153,249
-9% -$6.61M
PEN icon
3
Penumbra
PEN
$12.7B
$76.2M 5.7%
1,537,570
-25,017
-2% -$1.13M
ARRY
4
DELISTED
Array Biopharma Inc
ARRY
$75.3M 5.64%
17,850,650
+100,140
+0.6% +$457K
ITCI
5
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$65.8M 4.93%
1,223,717
-98,875
-7% -$4.99M
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$62.9M 4.7%
1,795,936
+838,302
+88% +$54.1M
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
$61.6M 4.61%
1,372,492
-17,681
-1% -$736K
TEVA icon
8
Teva Pharmaceuticals
TEVA
$42.5B
$61.6M 4.61%
938,139
-199,420
-18% -$12.3M
SAGE
9
DELISTED
Sage Therapeutics
SAGE
$55.9M 4.18%
958,374
-184,490
-16% -$9.14M
PTLA
10
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$49.3M 3.69%
958,155
+188,514
+24% +$9.14M
WCG
11
DELISTED
Wellcare Health Plans, Inc.
WCG
$44M 3.29%
562,873
+48,600
+9% +$4.03M
IRWD icon
12
Ironwood Pharmaceuticals
IRWD
$682M
$42.6M 3.18%
4,383,585
+4,155,783
+1,824% +$40.2M
BSX icon
13
Boston Scientific
BSX
$67.9B
$41.5M 3.11%
+2,251,020
New +$40.3M
PFE icon
14
CALL
Pfizer
PFE
$159B
$40.7M 3.04%
+1,328,462
New +$41.8M
ATRA icon
15
Atara Biotherapeutics
ATRA
$92.3M
$40.5M 3.03%
61,398
+19,407
+46% +$14.7M
INCY icon
16
Incyte
INCY
$25.2B
$38.8M 2.9%
357,912
-255,686
-42% -$28.5M
DPLO
17
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$38.2M 2.86%
+1,115,902
New +$34.8M
NVRO
18
DELISTED
NEVRO CORP.
NVRO
$28M 2.1%
415,198
+390,198
+1,561% +$20.9M
NDRM
19
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$27.1M 2.03%
1,589,261
+126,562
+9% +$2.47M
CNC icon
20
Centene
CNC
$32B
$26.9M 2.01%
816,000
-678,920
-45% -$20.1M
INSM icon
21
Insmed
INSM
$25.9B
$25.3M 1.89%
1,391,813
+443,847
+47% +$7.82M
UNH icon
22
UnitedHealth
UNH
$353B
$22M 1.65%
+187,034
New +$21.9M
AGN
23
DELISTED
Allergan plc
AGN
$21.5M 1.61%
+68,758
New +$20.5M
MODN
24
DELISTED
MODEL N, INC.
MODN
$20.8M 1.56%
1,868,159
+424,881
+29% +$4.53M
ZLTQ
25
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$20.2M 1.51%
+709,426
New +$22.4M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2015 Portfolio in Review

As of Q4 2015, Redmile Group held 73 positions worth $1.34B, up 1.2% from $1.32B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Redmile Group's Q4 2015 filing shows 15 new, 18 increased, 22 reduced and 16 closed positions. Its largest new stake was Boston Scientific: 2,251,020 shares worth $41.5M. The largest sale was Rite Aid Corporation, an estimated $49M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, down from 89% a quarter earlier, followed by Miscellaneous and Communication Services.

  • Redmile Group's largest Q4 2015 buy was Boston Scientific: 2,251,020 shares worth $41.5M.
  • Redmile Group added most to Clovis Oncology, Inc. in Q4 2015, an estimated $54.1M increase.
  • Redmile Group's biggest Q4 2015 reduction was Incyte, cutting an estimated $28.5M.
  • Redmile Group fully exited Rite Aid Corporation in Q4 2015, selling an estimated $49M.
  • Redmile Group's ten largest holdings make up 51% of its $1.34B portfolio in Q4 2015.
  • Redmile Group opened 15 new positions and closed 16 in Q4 2015.
  • Redmile Group's portfolio value rose 1.2% quarter-over-quarter to $1.34B.

Based on Redmile Group's 13F filing for Q4 2015, filed 16 Feb 2016.